Paper7201845
Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain.
Hirst DG and 2 others. Br J Cancer, 1982. Cited by 83 papers, by iCite.
Cite this record
ConductScience Library. Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain. Papers, record 7201845. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7201845
- Cell line
- SCC723 papers
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Cell lines1
Source Cell lines
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Lomustine | Major topic |
| Misonidazole | Major topic |
| Neoplasms, Experimental | Major topic |
| Nitroimidazoles | Major topic |
| Nitrosourea Compounds | Major topic |
| Animals | |
| Cell Survival | |
| Dose-Response Relationship, Drug | |
| Drug Synergism | |
| Hematopoietic Stem Cells | |
| Male | |
| Mice | |
| Mice, Inbred Strains | |
| Spermatogonia | |
| Time Factors |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| CA-15201 | NCI NIH HHS | United States | R01CA015201 | PubMed and NIH | NIH RePORTER |
| CA-25990 | NCI NIH HHS | United States | R01CA025990 | PubMed and NIH | NIH RePORTER |
| R37CA015201 | NIH | NIH RePORTER |
References17
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 7273265 | Structure-pharmacokinetic relationships for misonidazole analogues in mice. | Cancer Chemother Pharmacol | 1981 | https://conductscience.org/library/papers/7273265 | PubMed |
| 2 | 6457018 | SR-2508: a 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use. | Int J Radiat Oncol Biol Phys | 1981 | https://conductscience.org/library/papers/6457018 | PubMed |
| 3 | 6053718 | Factors influencing the quantitative estimation of the in vivo survival of cells from solid tumors. | J Natl Cancer Inst | 1967 | https://conductscience.org/library/papers/6053718 | PubMed |
| 4 | 6264941 | Modification of tumour and host response to cyclophosphamide by misonidazole and by WR 2721. | Br J Cancer | 1981 | https://conductscience.org/library/papers/6264941 | PubMed |
| 5 | 13776896 | A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. | Radiat Res | 1961 | https://conductscience.org/library/papers/13776896 | PubMed |
| 6 | 7272187 | Enhancing effect of misonidazole on the response of the RIF-1 tumour to cyclophosphamide. | Br J Cancer | 1981 | https://conductscience.org/library/papers/7272187 | PubMed |
| 7 | 7471058 | Enhancement of antitumor activity of alkylating agents by the radiation sensitizer misonidazole. | Cancer Res | 1980 | https://conductscience.org/library/papers/7471058 | PubMed |
| 8 | 7236488 | Enhanced cell killing in lewis lung carcinoma and a human pancreatic-carcinoma xenograft by the combination of cytotoxic drugs and misonidazole. | Br J Cancer | 1981 | https://conductscience.org/library/papers/7236488 | PubMed |
| 9 | 7459244 | In vivo response of KHT sarcomas to combination chemotherapy with radiosensitizers and BCNU. | Br J Cancer | 1981 | https://conductscience.org/library/papers/7459244 | PubMed |
| 10 | 7225287 | In vivo combination of misonidazole and the chemotherapeutic agent CCNU. | Br J Cancer | 1981 | https://conductscience.org/library/papers/7225287 | PubMed |
| 11 | 7248157 | Enhancement of the effect of cytotoxic drugs by radiosensitizers. | Br J Cancer | 1981 | https://conductscience.org/library/papers/7248157 | PubMed |
| 12 | 149333 | Gradual regeneration of mouse testicular stem cells after exposure to ionizing radiation. | Radiat Res | 1978 | https://conductscience.org/library/papers/149333 | PubMed |
| 13 | 476683 | Cytotoxic effects of chemotherapeutic drugs on mouse testis cells. | Cancer Res | 1979 | https://conductscience.org/library/papers/476683 | PubMed |
| 14 | 7459221 | In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: cyclophosphamide and BCNU. | Br J Cancer | 1980 | https://conductscience.org/library/papers/7459221 | PubMed |
| 15 | 7367588 | Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. | Radiat Res | 1980 | https://conductscience.org/library/papers/7367588 | PubMed |
| 16 | 47265 | Studies on recovery from chemically induced damage in mammalian cells. | Cancer Res | 1975 | https://conductscience.org/library/papers/47265 | PubMed |
| 17 | 150940 | DNA-protein cross-linking and DNA interstrand cross-linking by haloethylnitrosoureas in L1210 cells. | Cancer Res | 1978 | https://conductscience.org/library/papers/150940 | PubMed |
Cited by33
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 83 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 33665360 | Oncolytic activity of naturally attenuated herpes-simplex virus HF10 against an immunocompetent model of oral carcinoma. | Mol Ther Oncolytics | 2021 | https://conductscience.org/library/papers/33665360 | PubMed |
| 33326695 | Formulation of objective indices to quantify machine failure risk analysis for interruptions in radiotherapy. | J Appl Clin Med Phys | 2021 | https://conductscience.org/library/papers/33326695 | PubMed |
| 33053752 | Comprehensive Exome Analysis of Immunocompetent Metastatic Head and Neck Cancer Models Reveals Patient Relevant Landscapes. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/33053752 | PubMed |
| 32295135 | Tumor Membrane Vesicle Vaccine Augments the Efficacy of Anti-PD1 Antibody in Immune Checkpoint Inhibitor-Resistant Squamous Cell Carcinoma Models of Head and Neck Cancer. | Vaccines (Basel) | 2020 | https://conductscience.org/library/papers/32295135 | PubMed |
| 31477804 | Oncolytic activity of HF10 in head and neck squamous cell carcinomas. | Cancer Gene Ther | 2020 | https://conductscience.org/library/papers/31477804 | PubMed |
| 30696955 | Immune-relevant aspects of murine models of head and neck cancer. | Oncogene | 2019 | https://conductscience.org/library/papers/30696955 | PubMed |
| 30546955 | Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma. | Oncoimmunology | 2019 | https://conductscience.org/library/papers/30546955 | PubMed |
| 30016493 | Oral squamous carcinoma cells promote macrophage polarization in an MIF-dependent manner. | QJM | 2018 | https://conductscience.org/library/papers/30016493 | PubMed |
| 26063793 | Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases. | J Natl Cancer Inst | 2015 | https://conductscience.org/library/papers/26063793 | PubMed |
| 25299269 | A combretastatin-mediated decrease in neutrophil concentration in peripheral blood and the impact on the anti-tumor activity of this drug in two different murine tumor models. | PLoS One | 2014 | https://conductscience.org/library/papers/25299269 | PubMed |
| 18574138 | Pulsed high-intensity focused ultrasound enhances apoptosis and growth inhibition of squamous cell carcinoma xenografts with proteasome inhibitor bortezomib. | Radiology | 2008 | https://conductscience.org/library/papers/18574138 | PubMed |
| 11896468 | Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. | Gene Ther | 2002 | https://conductscience.org/library/papers/11896468 | PubMed |
| 8766532 | Changes in cell proliferative parameters of SCCVII and EMT6 murine tumors after single-dose irradiation. | Jpn J Cancer Res | 1996 | https://conductscience.org/library/papers/8766532 | PubMed |
| 8763875 | Changes in energy metabolism and X-ray sensitivity in murine tumours by the nitric oxide donor SIN-1. | Br J Cancer Suppl | 1996 | https://conductscience.org/library/papers/8763875 | PubMed |
| 8763848 | Tirapazamine: hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay. | Br J Cancer Suppl | 1996 | https://conductscience.org/library/papers/8763848 | PubMed |
| 8562329 | Combined effects of an angiogenesis inhibitor (TNP-470) and hyperthermia. | Br J Cancer | 1996 | https://conductscience.org/library/papers/8562329 | PubMed |
| 8431360 | Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies. | Br J Cancer | 1993 | https://conductscience.org/library/papers/8431360 | PubMed |
| 7150475 | Structure/activity relationships for the enhancement by electron-affinic drugs of the anti-tumour effect of CCNU. | Br J Cancer | 1982 | https://conductscience.org/library/papers/7150475 | PubMed |
| 6871076 | Chemosensitization by lipophilic nitroimidazoles. | Br J Cancer | 1983 | https://conductscience.org/library/papers/6871076 | PubMed |
| 6849803 | Modification of CCNU pharmacokinetics by misonidazole--a major mechanism of chemosensitization in mice. | Br J Cancer | 1983 | https://conductscience.org/library/papers/6849803 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/7201845
GET https://conductscience.org/api/papers/v1/7201845/cited_by?page=2